Plant Name: Chlamydomonas reinhardtii
Taxonomic Information:
Plant ID: NPO4011
Plant Latin Name: Chlamydomonas reinhardtii
Taxonomy Genus: Chlamydomonas
Taxonomy Family: Chlamydomonadaceae
Plant External Links:
NCBI TaxonomyDB:
3055
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; FFAR1; FFAR4; | |
| GRM1; GRM8; | |
| TSHR; | |
| HDAC1; | |
| BLM; FBP1; ADK; ALOX15; ALDH1A1; | |
| GRIA4; GRIA2; GRIK3; GRIK5; GRIK1; | |
| SRC; | |
| NR1H4; | |
| TP53; | |
| SLC1A1; | |
| LMNA; FABP3; FABP4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP3A4; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | FBP1 | Fructose-1,6-bisphosphatase | P09467 | CHEMBL3975 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Histone deacetylase | HDAC1 | Histone deacetylase 1 | Q13547 | CHEMBL325 |
| Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
| Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
| Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
| Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
| Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
| Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 4.555E-12 | 3.306E-08 | ADORA1, ADORA2A, GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
| MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 4.136E-11 | 1.287E-07 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
| BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 2.324E-10 | 5.623E-07 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
| MF | Unclassified; | GO:0004872; receptor activity | 3.341E-09 | 4.547E-06 | ADORA1, ADORA2A, ADORA3, FFAR1, FFAR4, GRIA2, GRIA4, GRIK1, GRIK3, GRIK5, GRM1, GRM8, NR1H4, TSHR |
| MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 2.431E-08 | 2.206E-05 | GRIK1, GRIK3, GRIK5 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 8.493E-08 | 6.164E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 2.034E-07 | 1.080E-04 | GRIK3, GRM1, GRM8 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 2.034E-07 | 1.080E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 1.960E-06 | 7.233E-04 | ADORA2A, HDAC1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 4.452E-06 | 1.346E-03 | FABP3, FFAR1, NR1H4, SRC |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 5.640E-06 | 1.574E-03 | ADORA1, ADORA2A |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 6.966E-06 | 1.873E-03 | FABP3, FABP4, FFAR4 |
| CC | GO:0043226; organelle | GO:0014069; postsynaptic density | 7.230E-06 | 1.897E-03 | ADORA1, ADORA2A, GRIK5, GRM1, SRC |
| MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 1.127E-05 | 2.697E-03 | GRIA2, GRIA4 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 1.520E-05 | 3.558E-03 | ADORA1, ADORA2A, FFAR4, HDAC1, LMNA, NR1H4, SRC, TP53 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.882E-05 | 4.269E-03 | ADORA1, ADORA2A, FFAR4, NR1H4 |
| BP | GO:0023052; signaling | GO:0046883; regulation of hormone secretion | 2.846E-05 | 6.197E-03 | ADORA1, ADORA2A, FFAR1, HDAC1, NR1H4 |
| CC | GO:0044425; membrane part | GO:0008328; ionotropic glutamate receptor complex | 3.552E-05 | 7.228E-03 | GRIA2, GRIA4, GRIK5 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 3.891E-05 | 7.845E-03 | ADORA1, ADORA2A, ADORA3, FABP3, HDAC1, LMNA, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 3.160E-14 | 3.476E-12 | GRIA2, ADORA2A, GRIK5, ADORA3, GRM8, GRIK3, ADORA1, GRIK1, TSHR, GRM1, GRIA4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04724 | Glutamatergic synapse | 1.762E-12 | 9.689E-11 | GRIA2, GRIK5, SLC1A1, GRM8, GRIK3, GRIK1, GRM1, GRIA4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 6.266E-06 | 2.297E-04 | GRIA2, ADORA2A, ADORA1, TSHR, GRIA4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 5.799E-05 | 1.595E-03 | FABP4, ADORA1, TSHR |
| 09160 Human Diseases | 09164 Substance dependence | hsa05031 | Amphetamine addiction | 9.922E-05 | 2.183E-03 | GRIA2, HDAC1, GRIA4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 3.348E-04 | 6.138E-03 | GRIA2, GRM1, GRIA4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 5.281E-04 | 7.626E-03 | SRC, HDAC1, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 5.546E-04 | 7.626E-03 | ADORA3, ADORA1, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 6.967E-04 | 8.515E-03 | ALOX15, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; TP53; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A; GRIA2; GRIA4; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | GRM1; ADORA2A; ADK; GRIK1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | GRM1; ADORA1; ADORA2A; GRIK1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRM1; GRIK1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; SRC; TP53; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | SRC; TP53; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GRM1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; GRIK1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | GRIK1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; FFAR1; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA1; ADORA2A; ADORA3; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
